Our data and knowledge have made a significat contribution to drug development worldwide

We use our technology to support all aspects of preclinical drug discovery and biomedical translational research with a particular focus on disease of the nervous system.

Publications
Posters

Publications

NeuroSolutions has been performing first class contract research since 2001 and continues to support the biopharmaceutical industry in developing new treatments for diseases occurring throughout the central and peripheral nervous system.

Our particular strength in electrophysiology allows investigation of function in the naïve and diseased state at all levels of the neuraxis, and the contribution our data and knowledge have made, and continue to make, to drug development programs worldwide is significant.

Publication list

A small representation of the impact NeuroSolutions has made to neuroscience research since 2001 can be demonstrated by some of our recent publications:

2023

Pro-opiomelanocortin neurons in the nucleus of the solitary tract mediate endorphinergic endogenous analgesia in mice. Pain. 2023 May 1;164(5):1051-1066.
Relevent NSOLNS Publication

2022

Selective activation of Gαob by an adenosine A1 receptor agonist elicits analgesia without cardiorespiratory depression. Nat Commun. 2022 Jul 18;13(1):4150.
Relevent NSOLNS Publication

2021

Neuron-specific responses to acetylcholine within the spinal dorsal horn circuits of rodent and primate. Neuropharmacology. 2021 Oct 15;198:108755.
Relevent NSOLNS Publication

Alkyne-Bridged α-Conotoxin Vc1.1 Potently Reverses Mechanical Allodynia in Neuropathic Pain Models. J Med Chem. 2021 Mar 25;64(6):3222-3233.
Relevent NSOLNS Publication

2020

α-Conotoxin Peptidomimetics: Probing the Minimal Binding Motif for Effective Analgesia. Toxins (Basel). 2020 Aug 6;12(8):505.
Relevent NSOLNS Publication

A Neural basis for Octanoic acid regulation of energy balance. Mol Metab. 2020 Apr;34:54-71.
Relevent NSOLNS Publication

2017

Mitochondrial uncoupling in the melanocortin system differentially regulates NPY and POMC neurons to promote weight-loss. Mol Metab. 2017 Oct;6(10):1103-1112.
Relevent NSOLNS Publication

The impact of ageing, fasting and high-fat diet on central and peripheral glucose tolerance and glucose-sensing neural networks in the arcuate nucleus. J Neuroendocrinol. 2017 Oct;29(10).
Relevent NSOLNS Publication

Does leptin cause an increase in blood pressure in animals and humans? Curr Opin Nephrol Hypertens. 2017 Jan;26(1):20-25.

2016

Pharmacology of reflex blinks in the rat: a novel model for headache research. J Headache Pain. 2016 Dec;17(1):96.

Hippocampal 5-HT7 receptors signal phosphorylation of the GluA1 subunit to facilitate AMPA receptor mediated-neurotransmission in vitro and in vivo. Br J Pharmacol. 2016 May;173(9):1438-51.
Relevent NSOLNS Publication

Lack of support for bexarotene as a treatment for Alzheimer's disease. Neuropharmacology. 2016 Jan;100:124-30.
Relevent NSOLNS Publication

2015

MRZ-99030 - A novel modulator of Aβ aggregation: II - Reversal of Aβ oligomer-induced deficits in long-term potentiation (LTP) and cognitive performance in rats and mice. Neuropharmacology. 2015 May;92:170-82.
Relevent NSOLNS Publication

Eslicarbazepine and the enhancement of slow inactivation of voltage-gated sodium channels: a comparison with carbamazepine, oxcarbazepine and lacosamide. Neuropharmacology. 2015 Feb;89:122-35.

2014

In vivo electrophysiological recording techniques for the study of neuropathic pain in rodent models. Curr Protoc Pharmacol. 2014 Sep 2;66:11.15.1-11.15.26.

Electrophysiological Techniques for Studying Synaptic Activity In Vivo. Curr Protoc Pharmacol. 2014 Mar 3;64:11.11.1-17.

 

"Thank you for the absolutely phenomenal work you have done for Redpin. As biotech managers, we frequently push CROs to the max and sometimes take them for granted. After reviewing the work that you have done over the past year, I felt that I needed to let you know what a difference you had made to Redpin’s growth and success. Your work has been of the highest caliber and your dedication unmatched."

Elma Hawkins PhD, MBA, former President and CEO Redpin Therapeutics, Inc.

"I have worked with NeuroSolutions on many projects over many years. The quality of the data is second to none, their scientific expertise and collaborative approach to our technicality demanding projects has been excellent. For example, the work on SEN1576 has led to high-impact joint publications with Senexis and this compound is now being developed by Talisman Therapeutics.."

Dr Mark Treherne - As former Chief Executive of Senexis Limited (Dr Treherne is currently Chief Executive of Life Sciences Organisation at UK Trade & Investment, which helps UK business trade overseas).

In partnership with
Science Exchange
Pacific Discovery Services
scientist.com
NeuroSolutions Ltd

Email: info@nsolns.com
Contact Head-office on +44 (0) 8454 500171


One of our partner companies may be better suited to your requirements

AUSTRALASIA
Pacific Discovery Services

Email: info@pacificdiscoveryservices.com